These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38587788)

  • 1. Three-year efficacy and safety of omidenepag isopropyl in patients with normal tension glaucoma.
    Inoue K; Shiokawa M; Kunimatsu-Sanuki S; Kang J; Uraki T; Tomita G; Ishida K
    Jpn J Ophthalmol; 2024 May; 68(3):206-210. PubMed ID: 38587788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma.
    Inoue K; Shiokawa M; Kunimatsu-Sanuki S; Nozaki N; Shimizu K; Ishida K; Tomita G
    J Ocul Pharmacol Ther; 2022 Jun; 38(5):354-358. PubMed ID: 35613407
    [No Abstract]   [Full Text] [Related]  

  • 3. Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma.
    Inoue K; Inoue J; Kunimatsu-Sanuki S; Nozaki N; Shimizu K; Ishida K; Tomita G
    Clin Ophthalmol; 2020; 14():2943-2949. PubMed ID: 33061280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
    Aihara M; Ropo A; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams N
    Jpn J Ophthalmol; 2020 Jul; 64(4):398-406. PubMed ID: 32572719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less.
    Nakano T; Yoshikawa K; Kimura T; Suzumura H; Nanno M; Noro T
    Jpn J Ophthalmol; 2011 Nov; 55(6):605-13. PubMed ID: 21874307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraocular pressure (IOP) reduction by latanoprost in Japanese normal tension glaucoma patients over a five-year period stratified by presenting IOP.
    Tsuda M; Ando A; Matsuyama K; Otsuji T; Fukui C; Maenishi N; Kuwahara A; Nishimura T; Jo N; Nambu H; Matsumura M
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):441-5. PubMed ID: 19857106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan.
    Nakazawa T; Takahashi K; Kuwayama Y; Nomura A; Shimada F
    Adv Ther; 2022 Mar; 39(3):1359-1374. PubMed ID: 35072890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphologic Changes in the Lamina Cribrosa Upon Intraocular Pressure Lowering in Patients With Normal Tension Glaucoma.
    Kim JA; Lee SH; Son DH; Kim TW; Lee EJ; Girard MJA; Mari JM
    Invest Ophthalmol Vis Sci; 2022 Feb; 63(2):23. PubMed ID: 35147659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preperimetric normal tension glaucoma study: long-term clinical course and effect of therapeutic lowering of intraocular pressure.
    Jeong JH; Park KH; Jeoung JW; Kim DM
    Acta Ophthalmol; 2014 May; 92(3):e185-93. PubMed ID: 24456145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of trabeculectomy on visual field progression in Japanese progressive normal-tension glaucoma with intraocular pressure < 15 mmHg.
    Naito T; Fujiwara M; Miki T; Araki R; Fujiwara A; Shiode Y; Morizane Y; Nagayama M; Shiraga F
    PLoS One; 2017; 12(8):e0184096. PubMed ID: 28850613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of long-term monitoring of normal-tension glaucoma patients receiving medical therapy: results of an 18-year follow-up.
    Komori S; Ishida K; Yamamoto T
    Graefes Arch Clin Exp Ophthalmol; 2014 Dec; 252(12):1963-70. PubMed ID: 25128961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
    Aihara M; Lu F; Kawata H; Iwata A; Liu K; Odani-Kawabata N; Shams NK
    J Glaucoma; 2019 May; 28(5):375-385. PubMed ID: 30839416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between the mean deviation slope and follow-up intraocular pressure in open-angle glaucoma patients.
    Fukuchi T; Yoshino T; Sawada H; Seki M; Togano T; Tanaka T; Ueda J; Abe H
    J Glaucoma; 2013 Dec; 22(9):689-97. PubMed ID: 23722866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of 0.002% Omidenepag Isopropyl on Intraocular Pressure and the Cornea in Normal Tension Glaucoma.
    Lee SH; Lee WJ; Kim KW; Jeong JH; Park IK; Chun YS
    J Glaucoma; 2023 Apr; 32(4):245-251. PubMed ID: 36729067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma.
    Naito T; Okuma S; Nagayama M; Mizoue S; Ozaki M; Namiguchi K; Miyamoto K; Tanito M; Yoshikawa K
    Adv Ther; 2016 Mar; 33(3):435-46. PubMed ID: 26861847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of a single XEN microstent implant for glaucoma patients with different types of glaucoma.
    Schargus M; Theilig T; Rehak M; Busch C; Bormann C; Unterlauft JD
    BMC Ophthalmol; 2020 Dec; 20(1):490. PubMed ID: 33334311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Follow-Up of Normal Tension Glaucoma Patients With TBK1 Gene Mutations in One Large Pedigree.
    Quist TS; Johnson CA; Robin AL; Fingert JH
    Am J Ophthalmol; 2020 Jun; 214():52-62. PubMed ID: 31987900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan.
    Miki A; Miyamoto E; Ishida N; Shii D; Hori K;
    Adv Ther; 2022 May; 39(5):2085-2095. PubMed ID: 35287233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of palmitoylethanolamide on visual field damage progression in normal tension glaucoma patients: results of an open-label six-month follow-up.
    Costagliola C; Romano MR; dell'Omo R; Russo A; Mastropasqua R; Semeraro F
    J Med Food; 2014 Sep; 17(9):949-54. PubMed ID: 24827384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study.
    Aihara M; Lu F; Kawata H; Iwata A; Odani-Kawabata N
    Jpn J Ophthalmol; 2021 Nov; 65(6):810-819. PubMed ID: 34495425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.